J Korean Ophthalmol Soc > Volume 52(1); 2011 > Article
Journal of the Korean Ophthalmological Society 2011;52(1):34-40.
DOI: https://doi.org/10.3341/jkos.2011.52.1.34    Published online January 15, 2011.
Long-term Therapeutic Effect of Intravitreal Bevacizumab (Avastin) on Myopic Choroidal Neovascularization.
Young Seung Seo, Moo Hwan Chang
Department of Ophthalmology, Dankook University Hospital, Cheonan, Korea. changmh@dankook.ac.kr
근시성 맥락막 신생혈관에 대한 유리체강내 베바시주맙 주입술 장기간 치료효과
서영승ㆍ장무환
Department of Ophthalmology, Dankook University Hospital, Cheonan, Korea
Abstract
PURPOSE
To evaluate the long-term therapeutic effects of intravitreal bevacizumab on myopic choroidal neovascularization (CNV). METHODS: Medical records of 6 patients who underwent intravitreal bevacizumab injection for myopic CNV and were followed for more than 2 years, were retrospectively investigated. The best corrected visual acuity was compared at 1,3,12, and 24 months after injection. Two years after the injection, a fluorescein angiography and optical coherence tomography (OCT) were performed to evaluate the central macular thickness and leakage of CNV. RESULTS: The mean best corrected visual acuity was 1.16 +/- 0.43 (logMAR), 0.45 +/- 0.21 (logMAR), 0.29 +/- 0.23 (logMAR), 0.14 +/- 0.11 (logMAR), and 0.11 +/- 0.06 (logMAR) at baseline, 1, 3, 12, and 24 months after injection, respectively. CONCLUSIONS: Intravitreal bevacizumab injection for the treatment of myopic CNV was effective in maintaining postoperative visual acuity for 2 years.
Key Words: Bevacizumab;Choroidal neovascularization;Intravitreal injection;Long-term;Myopic CNV


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society. All rights reserved.

Developed in M2PI

Close layer
prev next